News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ArQule, Inc. (ARQL) Receives $3 Million Milestone from Kyowa Hakko


2/6/2008 8:45:30 AM

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that it has received a $3 million milestone payment from Kyowa Hakko Kogyo Co., Ltd. (Kyowa), marking the initiation by Kyowa of a Phase 1, dose escalation trial in Japan with ARQ 197, a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase. This payment was made under the terms of an exclusive license agreement signed between the two companies in April 2007.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES